[go: up one dir, main page]

SG11201608729RA - Membrane-adherent self-assembled systems for treatment of ocular disorders - Google Patents

Membrane-adherent self-assembled systems for treatment of ocular disorders

Info

Publication number
SG11201608729RA
SG11201608729RA SG11201608729RA SG11201608729RA SG11201608729RA SG 11201608729R A SG11201608729R A SG 11201608729RA SG 11201608729R A SG11201608729R A SG 11201608729RA SG 11201608729R A SG11201608729R A SG 11201608729RA SG 11201608729R A SG11201608729R A SG 11201608729RA
Authority
SG
Singapore
Prior art keywords
membrane
treatment
ocular disorders
assembled systems
adherent self
Prior art date
Application number
SG11201608729RA
Inventor
Shikha P Barman
Ritesh V Thekkedath
Anne-Marie Cromwick
Koushik Barman
Kevin L Ward
Original Assignee
Integral Biosystems Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integral Biosystems Llc filed Critical Integral Biosystems Llc
Publication of SG11201608729RA publication Critical patent/SG11201608729RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201608729RA 2014-05-01 2015-05-01 Membrane-adherent self-assembled systems for treatment of ocular disorders SG11201608729RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461987012P 2014-05-01 2014-05-01
PCT/US2015/028748 WO2015168523A1 (en) 2014-05-01 2015-05-01 Membrane-adherent self-assembled systems for treatment of ocular disorders

Publications (1)

Publication Number Publication Date
SG11201608729RA true SG11201608729RA (en) 2016-11-29

Family

ID=54359368

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201608729RA SG11201608729RA (en) 2014-05-01 2015-05-01 Membrane-adherent self-assembled systems for treatment of ocular disorders

Country Status (12)

Country Link
US (2) US9901544B2 (en)
EP (1) EP3137481B1 (en)
JP (1) JP6452725B2 (en)
KR (1) KR101890503B1 (en)
CN (1) CN106459137B (en)
AU (2) AU2015252908B2 (en)
CA (1) CA2946373C (en)
ES (1) ES2924768T3 (en)
MY (1) MY193694A (en)
NZ (1) NZ725028A (en)
SG (1) SG11201608729RA (en)
WO (1) WO2015168523A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170147B1 (en) * 2016-07-07 2021-08-17 Salvat Lab Sa Ophthalmic composition comprising castor oil and medium chain triglyceride
WO2018230711A1 (en) 2017-06-16 2018-12-20 学校法人同志社 Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
EP3639855A4 (en) * 2017-06-16 2021-03-17 The Doshisha COMPOUNDS HAVING A CASPASE-INHIBITING EFFECT, PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS FOR THE TREATMENT OR PREVENTION OF CORNEAL DOTHELIC SYMPTOMS, DISORDERS OR DISEASES AND USE OF THIS PHARMACEUTICAL AGENT
JP6931493B2 (en) * 2017-06-22 2021-09-08 ヨンスン ファイン ケミカル カンパニー,リミテッド Eye drop composition for glaucoma treatment
US11129862B2 (en) * 2017-08-30 2021-09-28 Johnson & Johnson Consumer Inc. Ophthalmic compositions
US11000530B2 (en) * 2017-09-01 2021-05-11 Murray And Poole Enterprises Ltd Methods and compositions for the treatment of ophthalmic conditions
JP7056480B2 (en) * 2017-09-08 2022-04-19 ライオン株式会社 Ophthalmic composition and tear oil layer stabilizer
CN109316440B (en) * 2018-09-29 2020-12-29 华中科技大学 A kind of temperature-sensitive liquid crystal nano-hydrogel and its preparation method and application
BR112021007140A2 (en) * 2018-10-24 2021-07-20 Ferring B.V. mucoadhesive pharmaceutical compositions of corticosteroids
GB201818043D0 (en) * 2018-11-05 2018-12-19 Waterford Institute Of Tech Artifical Tears
US20210353554A1 (en) * 2020-05-18 2021-11-18 Max Biology Co. Ltd. Lipid-polymer compositions and methods of use
US12102632B2 (en) 2020-08-26 2024-10-01 Somerset Therapeutics, Llc Quinolone dispersions
US11382910B2 (en) * 2020-08-26 2022-07-12 Somerset Therapeutics, Llc. Loteprednol and moxifloxacin compositions and methods
WO2022077060A1 (en) * 2020-10-13 2022-04-21 University Of South Australia Antimicrobial compositions and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716830B2 (en) * 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
PE20020146A1 (en) * 2000-07-13 2002-03-31 Upjohn Co OPHTHALMIC FORMULATION INCLUDING A CYCLOOXYGENASE-2 (COX-2) INHIBITOR
JP4049216B2 (en) * 2003-05-09 2008-02-20 ポーラ化成工業株式会社 Formulation with liquid crystal structure
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20050235740A1 (en) * 2004-04-27 2005-10-27 Guido Desie Method to improve the quality of dispersion formulations
WO2006009825A1 (en) * 2004-06-17 2006-01-26 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
US20080145430A1 (en) * 2004-12-08 2008-06-19 Santipharp Panmai Ophthalmic Nanoparticulate Formulation Of A Cyclooxygenase-2 Selective Inhibitor
CN101137369A (en) * 2005-02-09 2008-03-05 马库赛特公司 Formulations for ocular treatment
US8906392B2 (en) 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
WO2008011836A2 (en) * 2006-07-25 2008-01-31 Osmotica Corp. Ophthalmic solutions
JP2010064995A (en) * 2008-09-12 2010-03-25 Nikko Chemical Co Ltd Anti-inflammatory analgesic composition for external application
US8703922B2 (en) * 2009-12-25 2014-04-22 Chemgenesis Incorporated Low-viscosity liquid crystal compound
CN101773670A (en) * 2009-12-29 2010-07-14 中山大学 Liquid crystal medicine carrier
JP2012017318A (en) * 2010-06-07 2012-01-26 Nikko Chemical Co Ltd Liquid crystal and skin external preparation containing the same
US8772273B2 (en) * 2011-10-04 2014-07-08 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
HK1208161A1 (en) * 2012-05-03 2016-02-26 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
WO2013169647A1 (en) * 2012-05-08 2013-11-14 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof

Also Published As

Publication number Publication date
JP6452725B2 (en) 2019-01-16
MY193694A (en) 2022-10-25
AU2015252908B2 (en) 2017-12-07
JP2017514843A (en) 2017-06-08
CN106459137A (en) 2017-02-22
ES2924768T3 (en) 2022-10-10
CN106459137B (en) 2019-04-12
NZ725028A (en) 2019-01-25
US10603273B2 (en) 2020-03-31
AU2015252908A1 (en) 2016-10-27
CA2946373A1 (en) 2015-11-05
KR101890503B1 (en) 2018-08-21
EP3137481A1 (en) 2017-03-08
EP3137481A4 (en) 2017-12-27
KR20160147784A (en) 2016-12-23
US20180185275A1 (en) 2018-07-05
AU2018201596B2 (en) 2020-02-06
WO2015168523A1 (en) 2015-11-05
US9901544B2 (en) 2018-02-27
EP3137481B1 (en) 2022-07-06
CA2946373C (en) 2018-07-31
US20170049697A1 (en) 2017-02-23
AU2018201596A1 (en) 2018-03-29

Similar Documents

Publication Publication Date Title
IL288712B1 (en) Methods for the treatment of abnormal involuntary movement disorders
IL248732B (en) Compounds for treating ophthalmic diseases and disorders
SG11201608729RA (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
IL247515A0 (en) Cenicriviroc for the treatment of fibrosis
EP3191185A4 (en) Device for targeted treatment of dermastoses
EP3119911A4 (en) Methods for treating neurological disorders
IL249502B (en) Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies
GB201408387D0 (en) Treatment of respiratory disorders
SG11201708181RA (en) Methods for the treatment of inflammatory disorders
GB201607388D0 (en) Treatment of impulsivity-related disorders
EP3145525A4 (en) Use of microperoxidases for the treatment of carboxyhemoglobinemia
EP3200795A4 (en) Use of agents for treating fat-related disorders
PL2937084T3 (en) Method for the treatment of hypercholesterolemia
SI3903774T1 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of neurodegenerative diseases
HK40035958B (en) Apparatus for treatment of brain disorders
HK40088295A (en) Treatment of immune disorders
HK40087941A (en) Methods for the treatment of abnormal involuntary movement disorders
GB201602784D0 (en) New treatment of CFTR-related disorders
GB201506228D0 (en) Methods For The Treatment Of Cardivascular Disorders
GB201521543D0 (en) Methods for the treatment of inflammatory disorders
GB201513993D0 (en) Methods for the treatment of inflammatory disorders
GB201513345D0 (en) Methods for the treatment of Inflammatory disorders
EP3177316A4 (en) Method for preventing or treating ocular disorders
AU2014902194A0 (en) Treatment of immune disorders
GB201507113D0 (en) Methods for the treatment of inflammatory disorders